US Patent 9289477 Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses
Patent 9289477 was granted and assigned to SELECTA BIOSCIENCES INC on March, 2016 by the United States Patent and Trademark Office.
All edits
Edits on 4 Dec, 2023
Golden AI
Edits made to:
Article (+317 characters)
Article
Patent abstract
Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes.
Edits on 11 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 29 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Christopher Fraser0
Roberto A. Maldonado0
Takashi Kei Kishimoto0
Edits on 13 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09289477 Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses US Patent 9289477 Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses
Infobox
Patent Number
09289477
Patent Number
9289477
Edits on 26 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 5 Jan, 2022
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 09289477 Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
09289477
Date of patent
March 22, 2016
Patent application number
13457999
Date Filed
April 27, 2012
Patent primary examiner
Find more entities like US Patent 9289477 Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
